Agios Pharmaceuticals
AGIO
216 hedge funds and large institutions have $3.61B invested in Agios Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 48 funds opening new positions, 65 increasing their positions, 62 reducing their positions, and 27 closing their positions.
78% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 27
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
50% more call options, than puts
Call options by funds: $28.9M | Put options by funds: $19.2M
46% more capital invested
Capital invested by funds: $2.47B → $3.61B (+$1.14B)
10% more funds holding
Funds holding: 197 → 216 (+19)
5% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 62
3.32% less ownership
Funds ownership: 101.3% → 97.98% (-3.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$26.9M |
| 2 |
BlackRock
New York
|
+$22.1M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
+$15.6M |
| 4 |
GLA
Great Lakes Advisors
Chicago,
Illinois
|
+$15M |
| 5 |
MS
Maven Securities
St Helier,
Jersey
|
+$13.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$156M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$17.7M |
| 3 |
UBS AM
Chicago,
Illinois
|
-$17.2M |
| 4 |
HM
HealthCor Management
New York
|
-$14.5M |
| 5 |
M&T Bank
Buffalo,
New York
|
-$10.6M |
AGIO Hedge Fund Activity: Q2 2020 in Review
216 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q2 2020, worth a combined $3.61B — up 46% from $2.47B a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new AGIO positions and 27 closed out — a net gain of 21 holders — while 65 added to existing stakes and 62 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $26.9M. The largest seller was Fidelity Investments, cutting an estimated $156M.
- 216 institutional investors held Agios Pharmaceuticals (AGIO) as of Q2 2020, up from 197 in Q1 2020.
- Funds reported $3.61B of Agios Pharmaceuticals stock for Q2 2020, up 46% quarter-over-quarter.
- 48 funds opened new Agios Pharmaceuticals positions in Q2 2020 and 27 closed out, a net change of +21 holders.
- The largest Agios Pharmaceuticals buyer in Q2 2020 was T. Rowe Price Associates, an estimated $26.9M added.
- The largest Agios Pharmaceuticals seller in Q2 2020 was Fidelity Investments, an estimated $156M sold.
Based on aggregated 13F filings for Q2 2020.